Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes

Ítems similars

• A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4(+) T cells
  per: Paas-Rozner, Miri, et al.
  Publicat: (2003)
• A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses
  per: Katz-Levy, Yael, et al.
  Publicat: (1997)
• The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes
  per: Paas-Rozner, Miri, et al.
  Publicat: (2001)
• Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice
  per: Paas-Rozner, Miri, et al.
  Publicat: (2000)
• Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4(+)CD25(+) regulatory cells
  per: Aruna, Badiga Venkata, et al.
  Publicat: (2005)